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Abstract
Background: Compounds mimicking the inhibitory effect of SMAC / DIABLO on X-linked inhibitor of apoptosis (XIAP) have
been developed with the aim to achieve sensitization for apoptosis of tumor cells resistant due to deregulated XIAP
expression. It turned out that SMAC mimetics also have complex effects on the NFkB system and TNF signaling. In view of
the overwhelming importance of the NFkB transcription factors in the immune system, we analyzed here the effects of the
SMAC mimetic BV6 on immune cells.
Principal Findings: BV6 induced apoptotic and necrotic cell death in monocytes while T-cells, dendritic cells and
macrophages were largely protected against BV6-induced cell death. In immature dendritic cells BV6 treatment resulted in
moderate activation of the classical NFkB pathway, but it also diminished the stronger NFkB-inducing effect of TNF and
CD40L. Despite its inhibitory effect on TNF- and CD40L signaling, BV6 was able to trigger maturation of immature DCs as
indicated by upregulation of CD83, CD86 and IL12.
Significance: The demonstrated effects of SMAC mimetics on immune cells may complicate the development of tumor
therapeutic concepts based on these compounds but also arise the possibility to exploit them for the development of
immune stimulatory therapies.
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Introduction
SMAC (second mitochondria-derived activator of caspases) /
DIABLO (direct inhibitor of apoptosis-binding protein with low
isoelectric point) facilitates activation of apoptotic caspases by
releasing these proteins from the inhibitory interaction with
inhibitor of apoptosis proteins (IAPs), particularly XIAP [1,2].
SMAC is located in the mitochondria of normal cells, but after
permeabilization of the outer mitochondrial membrane in course
of apoptosis via the intrinsic pathway, it is released along with
proapoptotic proteins such as cytochrome c, which triggers the
assembly of the caspase-9 activating apoptosome. SMAC is a
dimer and interacts with its four N-terminal amino acid residues
(AVPI) with XIAP and the related proteins cIAP1 (cellular
inhibitor of apoptosis 1) and cIAP2. In case of XIAP this results in
the dissociation of bound caspases and thus easier induction of
apoptosis. In case of cIAP1 and cIAP2, SMAC binding triggers
autoubiquitination and proteasomal degradation of these mole-
cules [1,2].
Inappropriate apoptosis resistance is not only of central
relevance for the development of tumors per se but also a major
factor that drives the evolution of therapy refractory cancer cells.
No wonder, there were early on considerable efforts to design
molecules that mimic the activity of SMAC to use them in cancer
therapy. In fact, in a variety of in vitro tumor models, the principle
feasibility of this concept has been demonstrated [1,2]. However,
cIAP1 and cIAP2 have also a crucial role in the constitutive
degradation of the MAP3 kinase NIK (NFkB inducing kinase)
which is an essential signaling intermediate in the alternative
NFkB (nuclear factor kB) pathway [3–7]. cIAP1 and cIAP2
furthermore contribute to activation of the classical NFkB
pathway by a variety of stimuli including TNF [8–10]. Treatment
of cells with SMAC mimetics therefore regularly results in
activation of the alternative NFkB pathway and at least
occasionally to some extent also in activation of the classical
NFkB pathway. As cIAP1 and cIAP2 in addition antagonize
TNFR1-associated caspase-8 activation, SMAC mimetics further-
more sensitize cells for TNF-induced apoptosis [5,11,12]. Indeed,
SMAC mimetic-induced activation of the NFkB system can result
in the up-regulation of TNF which in turn secondarily kills in an
autocrine fashion the SMAC mimetic-sensitized cells [4,5,13–15].
The effects of SMAC mimetics on non-transformed primary
cells have been poorly addressed so far. In view of the
overwhelming importance of the NFkB system for the regulation
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21556of immune cells, we analyzed here the effects of the SMAC
mimetic BV6 on human primary immune cells. We found that
BV6 induces no or only moderate cell death in most immune cells
with exception of monocytes which proved to be quite sensitive.
BV6 treatment alone showed furthermore moderate activation of
the classical NFkB pathway in dendritic cells (DCs) but diminished
the stronger NFkB-inducing effect of TNF and CD40L in these
cells. Noteworthy, BV6 treatment was sufficient to drive
maturation of monocyte-derived DCs. Taken together, the effects
of SMAC mimetics on the immune system may complicate the
development of tumor therapeutic concepts based on these
compounds but there also arises the possibility to exploit them
for the development of immune stimulatory therapies.
Results
SMAC mimetic BV6 triggers p100 processing and inhibits
TNF-induced signaling
We synthesized the recently published bivalent SMAC mimetic
BV6 and furthermore generated a monomeric and a trimeric
variant derived thereof (Fig. 1). The trivalent variant (triSmM) and
BV6 were comparably active while the monovalent compound
(moSmM) was ten to twenty-fold less active. This was evident from
dose response analyses of SMAC mimetic-induced apoptosis of
Kym-1 cells (Fig. 2A,B), which in response to SMAC mimetics
undergo apoptosis due to the induction of endogenous TNF [4,5].
In view of the comparable activity of triSmM and BV6 we used in
the following in this study only the bivalent BV6 molecule. The
mode of action of BV6 was further confirmed by analyzing p100
processing, a biochemical hallmark of activation of the alternative
NFkB pathway, which is an easily verifiable direct consequence of
degradation of cIAP1 and cIAP2 [4,5]. So, in various cell lines
including Kym-1 (rhabdomyosarcoma), HT1080 (fibrosarcoma),
HT29 (colon carcinoma) and KMS-12-BMS (multiple myeloma),
a strongly increased p52/p100 ratio was detectable 6 hours post
BV6 treatment (Fig. 2C). There was also accumulation of NIK
(Fig. 2C) another well documented consequence of degradation of
cIAP1 and cIAP2 [4,5]. In further accordance with recent data,
showing that cIAP1 and cIAP2 also contribute to NIK-
independent activation of the classical NFkB pathway in response
to TNFR1 by ubiquitination of the TNFR1-associated kinase
RIP1 [9,10], we observed that BV6 attenuates TNF-induced
phosphorylation of IkBa (inhibitor of kB-a; Fig. 2D). In
accordance with a role of RIP1 ubiquitination in activation of
MAP kinase cascades [16,17], we further observed reduced
phosphorylation of JNK and p38 in response to TNF stimulation
in BV6-treated cells (Fig. 2D). Although BV6 priming diminished
TNFR1-induced phosphorylation of IkBa, JNK and p38, there
was nevertheless a slight increase of these responses by BV6
treatment alone (Fig. 2D). Thus, BV6 activates to some extent
proinflammatory pathways but the same time interferes with their
much stronger stimulation by TNF.
SMAC mimetic BV6 induces cell death in freshly isolated
human monocytes
To evaluate the effect of BV6 on peripheral blood monocytes,
the latter was freshly isolated from buffy coats by ficoll density
centrifugation and anti-CD14 magnetic bead separation.
Monocytes were then immediately challenged with 10 mM
BV6 or remained untreated. MTT analysis and microscopic
inspection of monocytes of buffy coat preparations of various
independent blood donations revealed that treatment with BV6
strongly reduces the viability of monocytes (Fig. 3A,B). FACS
analyses correspondingly showed an increase in annexin-V
positive cells from 10–15% to 50–60% (Fig. 3C). Moreover,
western blot analyses revealed that there was processing of the
initiator caspase-8, the effector caspase-3 and the effector
caspase substrate PARP-1 (Fig. 3D). Cultivation of freshly
isolated monocytes was accompanied by an upregulation of
p100 and the anti-apoptotic proteins TRAF1 and FLIPL
(Fig. 3E). Basal expression of cIAP1, cIAP2 and xIAP in
monocytes varied between different donors but there was
typically a significant upregulation of xIAP upon overnight
cultivation (Fig. 3E). Noteworthy, induction of p100, TRAF1,
FLIPL and xIAP occurred irrespective of supplementation of the
culture medium with GM-CSF/IL4 which we regularly
included in the cell culture medium to drive maturation into
dendritic cells (Fig. 3E). In accordance with the common mode
of action of SMAC mimetics, cIAP1 and cIAP2 were practically
not detectable in BV6-treated cells. There was further an almost
complete processing of p100. We also noted a strong reduction
of xIAP expression in BV6-treated cells (Fig. 3E). This was
unexpected as it has been shown that BV6 triggers autoubiqui-
tination and degradation of cIAP1 and cIAP2 but not of xIAP
[4]. CD14 expression moderately declined overnight and this
was accelerated in BV6-treated cells. Again this effect occurred
irrespective whether cells were treated or not with GM-CSF/
IL4 (Fig. 3F).
Next, we evaluated the mechanisms of BV6-induced cell death.
The pan-caspase inhibitor z-VAD-fmk showed no protective
effect and even resulted regularly in a further reduction of
viability of BV6-treated monocytes (Fig. 4A). However, necros-
tatin-1 an inhibitor of RIP1, which in concert with RIP3 can
trigger necrosis [18], attenuated BV6-induced cell death (Fig. 4A).
Moreover, when z-VAD-fmk was coapplied with this inhibitor
[19], BV6-treated monocytes were almost completely rescued
(Fig. 4A). It is well known for TNFR1 and other death receptors
that these molecules can induce apoptotic and necrotic cell death
dependent on the cell type. As monocytes showed cell surface
expression of membrane TNF and TNFR1 (Fig. 4B), we
evaluated whether TNFR1 activation by endogenous TNF is
involved in SMAC mimetic-induced killing of monocytes. For this
purpose, we challenged cells with BV6 in the presence of a high
concentration of Enbrel, a TNFR2-Fc fusion protein approved
for the treatment of autoimmune diseases such as rheumatoid
arthritis. Although, there was a moderate inhibition of cell death
induction in some cases, statistical significant protection over all
samples analyzed were not achieved (Fig. 4A and data not
shown). Thus, sensitization for apoptotic signaling initiated by
endogenously produced TNF may contribute to BV6-induced cell
death but seems to play no obligate role. As monocytes also
express the death receptors TRAILR2 and CD95 (Fig. 4B), we
analyzed the effect of BV6 on monocyte viability not only in the
presence of Enbrel but also in the presence of Fc fusion proteins
of TRAILR2 and CD95. The Fc fusion protein concentrations
used were sufficient to rescue HT1080 cells from the apoptotic
effect of exogenously applied TRAIL, CD95L and TNF (Fig. 4C).
However, there was again no major protective effect even when
Enbrel was used in combination with TRAILR2-Fc and CD95-
Fc (Fig. 4C).
SMAC mimetic BV6 induces no or only hardly cell death
in monocyte-derived immune cells and T-cells
When monocytes were cultured in the presence of GM-CSF
and IL4 they rapidly become resistant for BV6-induced cell
death. Already one day treatment with these cytokines rendered
monocytes almost completely resistant against BV6, although
p100 processing was still efficiently triggered (Fig. 5A,B).
SMAC Mimetic Effects on Immune Cells
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monocytes were efficiently differentiated into immature dendritic
cells (iDCs), they were still poorly killed by BV6 and this also
holds true when iDCs were further differentiated with CD40L
into mature DCs (mDCs) (Fig. 6A). An alternative route of
differentiation of monocytes, which is triggered by M-CSF, results
in the generation of macrophages (MW). Again, this path of
monocyte differentiation was associated with resistance against
BV6-induced cell death in 5 of 6 independent samples indicating
that MW are typically SMAC mimetic insensitive. Western blot
analyses of p100 processing indicated that in all cell types
treatment with BV6 resulted in the activation of the alternative
NFkB pathway (Fig. 6B,C). In view of the inhibitory effect of BV6
on the expression of anti-apoptotic factors in freshly isolated
monocytes shown in figure 3E, we also analyzed the expression of
IAPs, TRAF1, FLIPL and Bcl-xL in immature DCs and DCs
maturated with TNF and CD40L. As expected, expression levels
of cIAP1 and cIAP2 were severely reduced in BV6-treated DCs
(Fig. 6C). Expression of xIAP was also reduced in BV6-treated
DCs but to a much lower extent than in monocytes (Fig. 3E and
6C). Bcl-xL, TRAF1 and cFLIPL are constitutively expressed in
iDCs and expression of these molecules was further increased
upon maturation with TNF or CD40L (Fig. 6C). More
interesting, however, BV6 induced expression of Bcl-xL, TRAF1
and cFLIPL in immature DCs reaching levels comparable to
those observed in mature DCs (Fig. 6C). Noteworthy, there was
no or only a comparably modest increase in the expression of
these molecules in BV6-treated mDCs (Fig. 6C). Thus, apart
from the inhibitory effect of BV6 on its direct targets cIAP1 and
cIAP2, BV6 elicits opposing effects on the expression of several
Figure 1. Based on peptide 1 which was synthesized using standard Fmoc solid phase methods on SASRIN
TM resin, BV6 (peptide 3)
and monovalent (peptide 2) and trivalent (peptide 4) variants derived thereof were synthesized.
doi:10.1371/journal.pone.0021556.g001
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the different sensitivity of these cell types for the cytotoxic effect
of BV6.
Irrespective of their activation status, T-cells isolated from
peripheral blood mononuclear cells were also found to be resistant
against BV6 (Fig. 7A). In this case, however, BV6 only induced a
moderate increase in the ratio of p52 to p100 (Fig. 7B). Taken
together, although it appears that BV6 consistently act on the
molecular level in immune cells, this may translate only in a subset
of these cells in cell death induction.
SMAC mimetic BV6 triggers alternative NFkB signaling in
dendritic cells but inhibits TNF- and CD40L-induced
activation of the classical NFkB pathway
Next, we evaluated whether BV6 interferes with cIAP1/2-
dependent non-apoptotic pathways induced by TNF or the related
cytokine CD40L. We thus treated iDCs overnight with BV6 and
analyzed the next day TNF- and CD40L-induced phosphorylation
of IkBa as an indicator of activity of the classical NFkB pathway.
There was hardly detectable IkBa phosphorylation in non-
stimulated iDCs, but both cytokines induced after 5 min
significant IkBa phosphorylation which was after 20 min already
again reduced (Fig. 8A). Priming of the iDCs with BV6 resulted in
a significant increase in basal IkBa phosphorylation that almost
reached the level of TNF-/CD40L-treated cells. TNF- and
CD40L-inducible IkBa phosphorylation, however, was almost
completely blocked (Fig. 8A). Similar results were obtained when
TNF- and CD40L-induced phosphorylation of p38 was analyzed.
Again both cytokines induced a significant response which was
attenuated in the BV6-primed cells (Fig. 8A). To further
investigate the effects of BV6 on TNF and CD40L signaling in
mature DCs, we maturated iDCs with CD40L for three days.
Prior analysis of TNF and CD40L signaling in the obtained
mDCs, cells were cultivated in CD40L-free medium for one day.
Then BV6 were added overnight or not and TNF- and CD40L-
induced phosphorylation of IkBa and p38 was analyzed by
western blotting (Fig. (8B). The results obtained were essentially
similar to those with iDCs. Thus, pretreatment with BV6 again
lead to some phosphorylation of p38 and IkBa, but in parallel
inhibited the more efficient phosphorylation of these molecules
that can be observed in response to TNF and CD40L in untreated
mDCs (Fig. 8B).
BV6 is sufficient to drive maturation of monocyte-derived
dendritic cells
A major consequence of p100 to p52 processing is the
conversion of p100/RelB heterodimers residing in the cytosol
towards p52/RelB heterodimeric complexes that were able to
translocate into the nucleus where they stimulate transcription of
target genes of the alternative NFkB pathway [20]. Notably, DCs
derived from RelB deficient mice are impaired in antigen
presentation and T-cell stimulation and the p52 precursor p100
has been furthermore identified as an inhibitor of dendritic cell
maturation [21,22]. We therefore evaluated the effect of BV6 on
maturation of monocyte-derived iDCs. We analyzed cell surface
expression of the costimulatory molecules CD83 and CD86 that
were upregulated in course of DC maturation. 10 mM of BV6
potently induced cell surface expression of both molecules
(Fig. 8C). Indeed, upregulation of CD83 and CD86 was almost
as efficient as by high concentrations of the well established DC
maturation-inducing cytokines TNF and CD40L. Moreover, BV6,
like CD40L, also induced IL12 production (Fig. 8D). Due to the
strong CD83/CD86 inducing effect of BV6, it was not possible to
reliable prove a potential interference with TNF- and CD40L-
induced DC maturation.
Discussion
SMAC mimetics have been developed with the aim to obtain
drugs that allow sensitization of tumor cells for apoptosis
induction by other drugs or endogenous factors by releasing
apoptotic caspases from the inhibitory interaction with IAP
proteins, particular XIAP [1,2]. In fact, several groups reported
strong apoptotic effects of SMAC mimetics on tumor cells in vitro
[5,11–13,15]. However, the analysis of the mechanisms
underlying SMAC mimetic-induced cell death revealed an
unexpected mode of action. So, it was found that apoptosis
induction was due to the induction of TNF and subsequent
stimulation of the death receptor TNFR1 [4,5,15]. Notably,
m o s tt u m o rc e l l sa r en o tp e rs es e n s i t i v ef o rT N Fa n di n d e e di t
t u r n e do u tt h a tS M A Cm i m e t i c si na ddition sensitizes cells for
the apoptotic action of TNF [4,5,23]. The TNF-related SMAC
mimetic effects do not base on XIAP targeting and instead rely
on the fact that binding of SMAC mimetics to cIAP1 and cIAP2
induces the proteasomal degradation of these molecules. cIAP1
and cIAP2 are crucial negative regulators of the alternative
NFkB pathway [7], but have also an activating role in TNFR1-
induced stimulation of the classical NFkB pathway [9,10].
Furthermore, cIAP1 and cIAP2 inhibit TNFR1-associated
activation of caspase-8 [24]. In accordance, SMAC mimetics
strongly induce activation of the alternative NFkB pathway and
inhibit TNF-induced activation of the classical NFkB pathway
([4,5,10], Fig. 2). Nevertheless, SMAC mimetics also induce the
classical NFkB pathway to some extent although the underlying
mechanisms are unclear but may include crosstalk between the
two NFkB pathways or indirect effects of targets induced via the
alternative NFkB pathway.
In view of the complex effects of SMAC mimetics on NFkB
and TNF signaling and the overwhelming importance of the
NFkB system in immune cells, we reasoned that SMAC mimetics
also modulate the function of immune cells, an aspect that is
certainly of relevance for the development for SMAC mimetic-
based therapies. As a first step to a better understanding of the
Figure 2. BV6 and its monovalent and trivalent counterparts moSmM and triSmM induce apoptosis in Kym-1 cells and trigger p100
processing in a variety of cell lines. (A) Kym-1 cells were seeded in 96-well plates and stimulated the next day in triplicates with the indicated
concentrations of moSmM, BV6 and triSmM. After additional 18 h cell viability was determined by MTT staining. (B), Kym-1 cells were incubated in
triplicates overnight (16–18 h) with the indicated mixtures of z-VAD-fmk (20 mM), neutralizing TNF-specific mAb Remicade (40 mg/ml), TNF inhibitor
Enbrel (50 mg/ml) and the various SMAC mimetics (10 mM) and viability was then again determined by MTT staining. (C) The indicated cell lines were
treated with 10 mM BV6 for 6 hours or remained untreated. Total cell lysates were then analyzed with respect to the presence of the indicated
proteins by western blotting. (D) Kym-1 and HT1080 cells were primed with 10 mM BV6 for 6 h or remained untreated and were subsequently
stimulated for 0, 3, 10 min with TNF (30 ng/ml). Cells were lysed in Laemmmli sample buffer and analyzed by western blotting for the presence of the
indicated molecular species. Detection of phospho-IkBa, phospho-JNK and phospho-p38 is indicative for activation of the classical NFkB pathway
and the JNK and p38 MAP kinase cascades. An increase in the p52/p100 ratio further argues for enhanced signaling via the alternative NFkB pathway.
Detection of tubulin served as loading control.
doi:10.1371/journal.pone.0021556.g002
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this study the effects of the bivalent SMAC mimetic BV6 on
various types of human immune cells. First, we evaluated the
potential apoptotic effect of BV6. In most types of immune cells
namely macrophages, T-cells, immature and mature dendritic
cells, BV6 showed typically no significant effect on viability. In
freshly isolated monocytes, however, this compound triggered
pronounced cell death (Fig. 3). The inability of BV6 to induce cell
death in the majority of immune cells was not related to a general
‘‘inactivity’’ of this compound in these cell types because with
exception of activated T-cells all immune cells responded with a
strong increase in p100 processing to BV6 challenge (Fig. 5B, 6B,
and 7B) indicating an inhibitory effect on cIAP1/2. Studies with
the pan-caspase inhibitor z-VAD-fmk and the RIP1 inhibitor
necrostatin-1 showed that BV6-induced cell death in monocytes
base on triggering apoptosis and necrosis (Fig. 4A) pointing to
possible effect of TNF induction. Although, there was in some
experiments a minor protective effect of TNF-neutralizing
reagents, this reached no significance over all samples. Thus,
TNF signaling in monocytes seems to play no or only a secondary
role in BV6-induced killing of monocytes. We also evaluated the
possible implication of other endogenously produced death
ligands namely TRAIL and CD95L. Again neutralization of
any of these death ligands alone or together with TNF had no
major inhibitory effect on BV6-induced cell death (Fig. 4C).
However, we observed that BV6 treatment not only down-
regulated expression of cIAP1/2 but also the expression of xIAP.
The latter was unexpected as BV6 has been described to have no
major effect on xIAP expression but could reflect the recent
observation that xIAP, cIAP1 and cIAP2 form a complex and
stabilize each other [25]. Indeed, it has been shown that xIAP
deficiency as well as BV6 treatment sensitize some cells types for
cell death induction by the TNFR1-related death receptor CD95
in vivo [26]. In view of constitutive expression of membrane TNF
on monocytes (Fig. 4B), which allow autocrine or paracrine
TNFR1 signaling, one could thus speculate that BV6 sensitizes
monocytes for cell death induction by constitutively stimulated
TNFR1 and depletion of xIAP. The complex between membrane
TNF and TNFR1 might have already be formed prior monocyte
isolation and it could be difficult to resolve them afterwards by
adding soluble ligand-/receptor-specific blockers explaining the
poor protective effect of these compounds in our experiments (see
above). So, additional studies in the future must elucidate how
BV6-induced cell death operates in monocytes and should finally
clarify a possible involvement of TNFR1 or the other death
receptors.
BV6 treatment regularly induced cell death only in a fraction
(30–50%) of monocytes irrespective of GM-CSF/IL4 treatment
(Fig. 3 and data not shown). The only partial response is unlikely
to be caused by the failure of some monocytes to respond to BV6
but may rather reflect minor, stochastic differences in cellular
activities of survival and cytotoxic molecules. First, upon
sensitization of monocytes for necrosis by blocking caspases,
BV6 induced cell death in .90% of monocytes treated (Fig. 4A).
Second, BV6 triggered accelerated loss of CD14 expression in
monocytes surviving BV6 treatment (Fig. 3F). The latter may
mirror recent findings demonstrating that cIAP1 knockdown
reduces differentiation into macrophages of TPA-treated THP-1
cells and M-CSF-stimulated monocytes [27,28].
TNF and CD40L are potent triggers of maturation and
activation of DCs and utilize cIAPs for the activation of
proinflammatory pathways, including the classical NFkB pathway
and the p38 MAP kinase cascade. We thus analyzed the impact of
BV6 on TNF/CD40L-induced signaling in DCs. Not unexpected
in view of the cIAP degrading activity of SMAC mimetics, we
found that BV6 priming attenuates the capability of TNF and
CD40L to stimulate the activity of p38 and the classical NFkB
pathway in immature (Fig. 8A) and mature DCs (Fig. 8B).
Noteworthy, BV6 treatment alone led to an increase in the basal
activity of the classical NFkB pathway, however, without reaching
the strength of the cytokine-induced transient response (Fig. 8A,B).
More important, BV6 again induced p100 processing in DCs and
in accordance with then known inhibitory role of p100 in DC
maturation [22] this was sufficient to drive strong DC maturation
in vitro (Fig. 8C). Similar to TNF- and CD40L-driven maturation
of DCs, BV6-triggered DC maturation was accompanied by an
upregulation of NFkB-regulated anti-apoptotic factors including
FLIPL and Bcl-xL (Fig. 6C). As BV6 stimulates the classical and
the alternative NFkB pathway in DCs and as there can be
crosstalk between both pathways, future studies going beyond this
initial report must decipher the precise contribution of the two
NFkB pathways to BV6-induced DC maturation. It is hardly
possible to predict the long term and detailed effects of SMAC
mimetics on DC activity in vivo only based on in vitro data.
However, it is tempting to speculate that the DC maturation-
inducing, potentially immune-stimulatory effect of BV6 could
synergize with its established proapoptotic effect on tumor cells in
cancer therapeutic concepts. In fact, while this manuscript was in
preparation a costimulatory effect on T-cells and enhanced anti-
tumor immunity were demonstrated for the SMAC mimetic LBW-
242 [29].
In sum, we noticed four effects of BV6 on immune cells. Firstly,
apoptosis induction in monocytes, secondly activation of the
alternative NFkB pathway in all investigated immune cells, thirdly
enhanced basal but reduced cytokine inducible activation of the
classical NFkB pathway in dendritic cells and fourth a potent
maturation-inducing activity on DCs.
The diverse functions and the complex interplay of the various
cell types of the immune system make it difficult to speculate about
the consequences of SMAC mimetics in vivo in a conclusive
fashion. In view of the aim to use SMAC mimetics in cancer
therapy, however, it is evident that effects of SMAC mimetic on
the immune system must be considered especially in case of long
term treatment. Moreover, there may be even the chance to
exploit the immune regulatory effects of SMAC mimetics, e.g. for
immunotherapy of cancer.
Figure 3. SMAC mimetic BV6 induces cell death in monocytes. (A) Monocytes were isolated from peripheral blood mononuclear cells by
MACS separation, cultivated for 1 day in GM-CSF/IL4 supplemented medium in the presence and absence of 10 mM BV6 and finally visually inspected
by microscopy. (B) Monocytes were cultivated with 10 mM BV6 for 1 day and viability was assessed using the MTT assay (triplicates, left panel).
Viability of BV6 treated cells were normalized against corresponding control samples receiving no BV6 (n=7, right panel). (C) Effect of 10 mM BV6 on
monocyte viability was determined after overnight incubation by annexin-V staining. Left panel shows a representative analysis of one individual
sample and the right panel summarizes the data of monocytes independently derived from 5 buffy coat samples. The mean is indicated by a
horizontal line. (D) Freshly isolated monocytes (0 h) and monocytes cultivated overnight in GM-CSF/IL4 (24 h) were analyzed by western blotting with
respect to the processing of the indicated caspases and PARP-1. (E and F) Freshly isolated monocytes and monocytes cultivated in the presence of
the indicated mixtures of GM-CSF/IL4 and 10 mM BV6 were analyzed by western blotting (E) and FACS (F) with respect to the expression of the
indicated proteins. The western blot data shown were representative for two – four independent experiments.
doi:10.1371/journal.pone.0021556.g003
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21556Figure 4. BV6 induces apoptotic and necrotic cell death in monocytes. (A) Freshly isolated monocytes were incubated in GM-CSF/IL4
supplemented medium for 1 h with the indicated mixtures of z-VAD-fmk (20 mM), necrostatin-1 (70 mM) and the TNF inhibitor TNFR2-Fc/Enbrel
(50 mg/ml). Cells were then challenged overnight with 10 mM BV6 and cell viability was finally evaluated by help of the MTT assay. (B) Freshly isolated
monocytes and monocytes cultivated overnight in the presence of the indicated mixtures of GM-CSF/IL4 and 10 mM BV6 were analyzed by FACS for
cell surface expression of membrane TNF and the death receptors TNFR1, CD95 and TRAILR2. (C) Monocytes were challenged with BV6 in the
presence of soluble Fc fusion proteins of TRAILR2 (5 mg/ml), CD95 (50 mg/ml) and TNFR2 (Enbrel, 20 mg/ml) or a mixture of them. After 24 h viability
was determined using the MTT assay (Left panel). The functionality of the three Fc fusion proteins was controlled in cell death assays with HT1080
and recombinant 50 ng/ml TNF, 4 ng/ml Fc-CD95L and 50 ng/mlTRAIL (right panel). Data shown are representative for three independent
experiments.
doi:10.1371/journal.pone.0021556.g004
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PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21556Figure 5. GM-CSF and IL4 rapidly induce resistance against BV6-induced cell death in monocytes. (A and B) Monocytes were cultivated
in medium supplemented with GM-CSF/IL4 and were treated immediately or after 1 and 2 days with 10 mM BV6. One day after stimulation BV6
treated cells and a corresponding control sample cultivated without BV6 were analyzed by annexin-V staining (A) and western blotting (B).
doi:10.1371/journal.pone.0021556.g005
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Ethics Statement
Macrophages and dendritic cells have been differentiated from
monocytes isolated from rests of blood buffy coats of fully
anonymized donors obtained from the Institute of Clinical
Transfusion Medicine and Ha ¨motherapy of the University
Hospital Wu ¨rzburg and required no special written informed
consent. Peripheral blood samples for isolation of PBMCs were
obtained after written informed consent (study no. 15/06
approved by the ethic commission of the Medical Faculty of the
University of Wu ¨rzburg).
SMAC mimetic synthesis
We synthesized the recently published bivalent SMAC mimetic
BV6 and monomeric and trimeric variants thereof by methods
modified from those used by Vucic et al [4]. In brief, peptide 1
(Fig. 1) was synthesized from commercially available amino acids
using standard Fmoc solid phase methods on SASRIN
TM resin.
Methyl esters were introduced using thionylchloride and metha-
nol. All coupling reactions of peptide 1 to spacers have been done
with HATU and diisopropyl ethyl amine. Fmoc protecting groups
have been removed with piperidine in DMF. All compounds have
been purified using MPLC techniques running methanol/water
gradients containing 0.5% TFA. Structure and purity of the
various compounds were finally analyzed by NMR, mass
spectroscopy and HPLC.
Isolation of monocytes and differentiation of dendritic
cells and macrophages
Monocytes were isolated from blood buffy coats by density
centrifugation with LSM 1077 lymphocyte separation medium
(PAA Laboratories, Pasching, Austria) and subsequent separation
with anti-CD14 conjugated magnetic beads and a MidiMACS
Separator (Miltenyi Biotec, Bergisch Gladbach, Germany) follow-
ing the manufacturer’s recommendation. Purity of monocytes
(CD14
+ cells) was controlled by FACS and was regularly .95%.
Monocytes were resuspended in RPMI-1460 supplemented with
10% fetal calf serum (FCS), 1% penicillin/streptomycin (PenStrep)
(all PAA), 10 ng/ml IL4 (ImmunoTools GmbH, Friesoythe,
Germany) and 50 ng/ml GM-CSF (ImmunoTools GmbH) and
immediately prepared for the various experiments. For analysis of
cell viability using the MTT assay 0.5610
6 cells per well of a 96-
well plate were seeded in 150 ml medium. For western blot and
FACS analysis, 2610
6 monocytes per well were seeded in 1 ml in
a 24-well plate. Monocytes were differentiated into dendritic cells,
by replenishing GM-CSF and IL4 every second day and were used
for experiments with immature DCs after 7 days. To obtain
mature DCs, iDCs were cultivated for additional three days in the
presence of 200 ng/ml Fc-CD40L [30]. Successful differentiation
and maturation of dendritic cells were controlled by FACS
analysis of CD83, CD86 and CD40 induction. Macrophages were
obtained by cultivation of monocytes with 25 ng/ml M-CSF
(R&D Systems, Wiesbaden-Nordenstadt, Germany) for 7 days
with adding of fresh medium every second day. Differentiation of
monocyte-derived macrophages was controlled by FACS analysis
of CD14 and CD11b.
Isolation and treatment of T-cells
PBMCs were isolated by Ficoll-Paque density-gradient centri-
fugation of cells obtained after plateletpheresis of regular blood
donors who gave their written informed consent. CD4
+ and CD8
+
T-cells were selected with CD4
+ and CD8
+ MicroBeads (Miltenyi
Biotech, Germany) and MACS LS columns on the Quadro-
MACS
TM Separator according to the manufacturer’s protocol.
Purity of CD4
+ and CD8
+ T-cells was controlled by FACS and
was regularly .95%. CD4
+ or CD8
+ cells (3610
6) were seeded in
a 24-well plate in 1 ml RPMI 1640/10% FCS (Gibco) and were
immediately analyzed with respect to BV6-induced cell death or
were stimulated with 1 mg/ml phyto-hemagglutinin (Sigma) for 4–
7 days to obtain activated T-cells. For analysis of BV6-induced
effects, cells were washed three times with PBS to remove any
remaining mitogen and were then challenged with BV6 or
remained untreated as a control.
Annexin-V staining and MTT assay
Cells (5610
5) were treated as indicated, washed two times in
annexin-V staining buffer and were resuspended in 50 ml annexin-
V staining buffer supplemented with 1 ml annexin-V solution
(ImmunoTools GmbH). After incubation on ice in the dark for
15–20 min, cells were diluted with 100 ml annexin-V staining
buffer and analyzed using FACSCalibur (BD Biosciences,
Heidelberg, Germany). For determination of cellular viability cells
(Kym-1: 2610
4 cells per well; monocytes: 50610
4 cells per well)
were seeded in 96-well plates. Cells were treated as indicated and
cell viability was determined using MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazolium bromide; Sigma, Steinheim, Ger-
many) staining.
Western blot analysis
Cells were washed once in PBS and total cell lysates were
prepared by suspending cells (8610
6 cells per 100 mlf o rm o n o -
cytes, dendritic cells, macrophages and KMS cells; 1610
6 cells
for Kym-1, HT1080 and HT29 cells) in 46 Laemmli sample
buffer (4% SDS, 0.05 M dithiothreitol, 20% glycerol, 0.1 M
Tris, pH 8.0) supplemented with phosphatase inhibitor cock-
tails I and II (Sigma) and complete protease inhibitor cocktail
(Roche Diagnostics, Munich, Germany), sonification (ten
pulses) and heating for 5 min at 96uC. After clearance of total
cell lysates by centrifugation (10 min, 14000 g), samples were
separated by SDS-PAGE and transferred to nitrocellulose
membranes. Nonspecific binding sites were blocked in Tris-
buffered saline containing 0.1% Tween 20 and 5% dry milk
and membranes were then incubated with the indicated
primary antibodies. After removal of primary antibodies by
washing in PBS containing 0.1% Tween 20, antigen-antibody
complexes were detected by the help of horseradish peroxi-
dase-conjugated secondary antibodies (Dako, Hamburg, Ger-
many) and an ECL western blotting detection kit (Amersham
Biosciences Europe, Freiburg, Germany). Primary antibodies
Figure 6. Monocyte-derived dendritic cells and macrophages are barely sensitive for BV6-induced cell death. (A and B) Monocyte-
derived macrophages, immature and Fc-CD40L maturated monocyte-derived dendritic cells were challenged for one day with and without 10 mM
BV6. Cells were then analyzed by annexin-V staining for cell death induction (A; upper panel: representative analysis of one individual sample; lower
panel: summary of the data of 3 independent DC experiments and 6 independent experiments with monocytes and macrophages). p100 processing
were determined by western blotting and is shown for one representative experiment (B). (C) Monocytes cultivated overnight in GM-CSF/IL4, iDCs
obtained after 7 days of cultivation with GM-CSF/IL4 and mDCs maturated with TNF or Fc-CD40L were analyzed by western blotting with respect to
the expression of the indicated proteins (data shown are representative for four independent experiments).
doi:10.1371/journal.pone.0021556.g006
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PLoS ONE | www.plosone.org 11 June 2011 | Volume 6 | Issue 6 | e21556Figure 7. SMAC mimetic BV6 induce no cell death in T-cells. (A and B) CD4
+ and CD8
+ T-cells were isolated by magnetic bead separation and
were stimulated for 4–7 days with PHA or remained untreated. Cells were challenged with 10 mM or remained untreated as a control and were finally
analyzed by annexin-V staining for cell death induction (A; upper panel: representative analysis of one individual sample; lower panel: summary of the
data of 3 independent experiments). p100 processing was determined by western blotting and are shown for one representative experiment (B).
doi:10.1371/journal.pone.0021556.g007
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PLoS ONE | www.plosone.org 13 June 2011 | Volume 6 | Issue 6 | e21556used were specific for caspase-8 (kind gift from K. Schulze-
Osthoff; University of Tu ¨ b i n g e n ) ,c a s p a s e - 3 ,N I K ,p h o s p h o -
IkBa, p38, phospho-p38, JNK, phospho-JNK (all Cell
Signaling, Frankfurt, Germany), Bcl-xL (S-18) IkBa (Santa
Cruz Biotechnologies Inc., Heidelberg, Germany), p100/p52
(Upstate Biotech, Schwalbach, Germany), cIAP2, PARP1 (BD
Biosciences Pharmingen, Heidelberg, Germany), cIAP1 (1E1-
1-10), FLIP (NF6) (Enzo Life Sciences, Lo ¨rrach, Germany) and
tubulin (Dunn, Asbach, Germany).
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Figure 8. SMAC mimetic BV6 attenuates TNF- and CD40L-induced proinflammatory signaling and triggers DC maturation. (A and B)
Immature monocyte-derived dendritic cells (iDCs) were generated by cultivation for 7 days with GM-CSF/IL4. To obtain mature dendritic cells (mDCs),
iDCs were further treated with Fc-CD40L (200 ng/ml) for 2 days. mDCs were then cultivated in Fc-CD40L–free medium for additional 24 hours with
and without 10 mM BV6 and were stimulated for the indicated times with TNF (200 ng/ml) and Fc-CD40L (200 ng/ml) (A). iDCs were primed overnight
with 10 mM BV6 and were then challenged for 5 and 20 min with TNF (200 ng/ml) and Fc-CD40L (200 ng/ml) (B). iDCs and mDCs were finally
analyzed by western blotting to determine the presence of the indicated proteins. The results shown with mDCs are representative of three
independent experiments, the results with iDCs for two experiments. (C) iDCs were treated with 10 mM BV6, 300 ng/ml TNF and 1 mg/ml of Flag-
CD40L oligomerized with 1 mg of the Flag-specific mAb M2 or as a control remained untreated. After three days cells were analyzed by FACS for the
cell surface expression of CD83 and CD86. (upper panel: representative analysis of one individual sample; lower panel: summary of the data of iDCs of
4 independent donors. (D) Cell culture supernatants from ‘‘C’’ were analyzed for the presence of IL12. IL12 production was normalized to the
corresponding values of untreated cells. The average of experiments with five independent donors is shown.
doi:10.1371/journal.pone.0021556.g008
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